LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study - Concepedia

Concepedia

Publication | Open Access

LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study

DOI Full Paper Access

18

Citations

0

References

2024

Year

N. Girard, Mauricio Burotto, L.G. Paz-Ares, Martin Reck, M. Schenker, A. Lingua, F.J. Orlandi, J. Naidoo, E.K. Beardlsey, Vamsidhar Velcheti,

Annals of Oncology

No additional data available for this publication yet. Check back later!